Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Plasma cell 2Other hematologic neoplasm 2Myeloid 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 12Multiple Myeloma 11Recurrence 8Lymphoma, Large B-Cell, Diffuse 4Sarcoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Endometrial Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, B-Cell 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Congenital Abnormalities 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumors 1Sarcoma, Endometrial Stromal 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Neurofibrosarcoma 1

Interventions

Rituximab 205Cyclophosphamide 178Peripheral Blood Stem Cell Transplantation 93Etoposide 91fludarabine phosphate 86Filgrastim 81Melphalan 62Vincristine 60Mycophenolic Acid 58Busulfan 58Whole-Body Irradiation 57Cytarabine 51Radiotherapy 49Doxorubicin 49Cyclosporine 49Tacrolimus 48Granulocyte Colony-Stimulating Factor 48Prednisone 46fludarabine 45Bendamustine Hydrochloride 45Methotrexate 44Carmustine 36Antilymphocyte Serum 34Dexamethasone 32Bortezomib 29Gemcitabine 27ibritumomab tiuxetan 25Methylprednisolone 23sargramostim 22Stem Cell Transplantation 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Lymphoma, Non-Hodgkin × selinexor × Clear all
NCT04640779 2026-05-28

Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 1 Completed
22 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT03955783 2024-10-26

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse

NCT01607892 2023-01-26

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Karyopharm Therapeutics Inc

Phase 1 Completed
286 enrolled 26 charts
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡